Pacific Biosciences of California, Inc. (PACB): Price and Financial Metrics

Pacific Biosciences of California, Inc. (PACB): $30.96

-3.38 (-9.84%)

POWR Rating

Component Grades













PACB Stock Summary

  • With a price/earnings ratio of 225.53, Pacific Biosciences Of California Inc P/E ratio is greater than that of about 96.27% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for Pacific Biosciences Of California Inc is higher than 98.53% of stocks in our set with a positive cash flow.
  • The volatility of Pacific Biosciences Of California Inc's share price is greater than that of 97.01% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to PACB, based on their financial statements, market capitalization, and price volatility, are BMRN, FORM, AMPH, CORT, and AOSL.
  • PACB's SEC filings can be seen here. And to visit Pacific Biosciences Of California Inc's official web site, go to

PACB Stock Price Chart Interactive Chart >

Price chart for PACB

PACB Price/Volume Stats

Current price $30.96 52-week high $53.69
Prev. close $34.34 52-week low $2.20
Day low $30.56 Volume 4,406,185
Day high $34.07 Avg. volume 5,377,874
50-day MA $34.57 Dividend yield N/A
200-day MA $15.33 Market Cap 5.98B

Pacific Biosciences of California, Inc. (PACB) Company Bio

Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The company was formerly known as Nanofluidics, Inc. The company was founded in 2000 and is based in Menlo Park, California.

PACB Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$30.96$0.36 -99%

Below please find a table outlining a discounted cash flow forecast for PACB, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Pacific Biosciences Of California Inc ranked in the 4th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Pacific Biosciences Of California Inc, consider:

  • Its compound free cash flow growth rate, as measured over the past 0.81 years, is -0.13% -- higher than only 11.92% of stocks in our DCF forecasting set.
  • Relative to other stocks in its sector (Healthcare), Pacific Biosciences Of California Inc has a reliance on debt greater than only 8.97% of them.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as PACB, try ALC, HALO, LNTH, VERU, and AGHC.

PACB Latest News Stream

Event/Time News Detail
Loading, please wait...

PACB Latest Social Stream

Loading social stream, please wait...

View Full PACB Social Stream

Latest PACB News From Around the Web

Below are the latest news stories about Pacific Biosciences Of California Inc that investors may wish to consider to help them evaluate PACB as an investment opportunity.

Pacific Biosciences Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of Pacific Biosciences common stock and restricted stock units (“RSUs”) covering 40,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on February 25, 2021. The 2020 Inducement Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee di...

Yahoo | March 2, 2021

Children’s Mercy Kansas City Expands Investment in Pacific Biosciences Sequel IIe Systems to Scale Up Whole Genome Research Initiatives Focused on Rare Disease Diagnosis

PacBio’s highly accurate HiFi sequencing will help clinical researchers identify disease-causing genetic variants and increase our understanding of rare diseasesKANSAS CITY, Mo. and MENLO PARK, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that Children’s Mercy Kansas City, one of the nation’s top pediatric medical centers, has increased its investment in highly accurate HiFi sequencing with four new Sequel IIe Systems to add to its two existing Sequel IIe Systems. These additional systems will significantly increase Children’s Mercy’s large-scale whole genome sequencing capacity and help accelerate its initiatives focused on identifying potential disea...

Yahoo | February 24, 2021

Acacia Research: Next Generation Genomic Sequencing At A Bargain Price

Acacia Research Corporation (ACTG) Next generation genomic sequencing at a bargain price Note by Quintessential Capital Management Friday, February 12, 2021 IMPORTANT: The following text contains important hyperlinks and footnotes By Quintessential Capital Management Usually market operators are left with the painful choice of being either “value” or “growth” investors....

Gabriele Grego on Seeking Alpha | February 19, 2021

Results: Pacific Biosciences of California, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Pacific Biosciences of California, Inc. ( NASDAQ:PACB ) just released its latest annual results and things are looking...

Yahoo | February 12, 2021

Pacific Biosciences of California, Inc. (PACB) CEO Christian Henry on Q4 2020 Results - Earnings Call Transcript

Pacific Biosciences of California, Inc. (PACB) Q4, 2020 Earnings Conference Call February 10, 2021 04:30 PM ET Company Participants Trevin Rard - Investor Relations Christian Henry - President & Chief Executive Office Susan Kim - Chief Financial Officer Mark Van Oene - Chief Operating Officer Conference Call Participants Doug Schenkel...

SA Transcripts on Seeking Alpha | February 11, 2021

Read More 'PACB' Stories Here

PACB Price Returns

1-mo -9.42%
3-mo 63.38%
6-mo 378.52%
1-year 789.66%
3-year 1,200.84%
5-year 255.45%
YTD 19.35%
2020 404.67%
2019 -30.54%
2018 180.30%
2017 -30.53%
2016 -71.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9716 seconds.